Karyopharm Therapeutics

KPTI · Nasdaq · United States

Share price · KPTI

$0.02-1.94 (-99.11%) 3M

no price since 10 Nov 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KPTI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-56.5%
  2. 2 Nov 2026-83.1%
  3. 28 Oct 2026+73.4%
  4. 22 Oct 2026+28.7%
  5. 14 Oct 2026-26.3%
  6. 1 Oct 2026-29.0%
  7. 29 Sep 2026-25.6%
  8. 31 Jul 2026-72.6%
  9. 20 Jul 2026-21.5%
  10. 15 May 2026-13.8%

Share of unusual movement by asset

For each asset, the share of KPTI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Selinexor
events and moves
2316%
Other company news (earnings, financing, releases naming no asset)—31%
Sessions with no dated event—53%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
XPO1 (exportin-1)Small molecule
Multiple MyelomaMyelofibrosisEndometrial Cancer
Phase 1/2
XPO1 (exportin-1)
Multiple Myeloma

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SelinexorPhase 2/3Relapsed/Refractory Diffuse Large B-cell Lymphoma
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
2027 (2)
April 2027 (1)
SelinexorPhase 1/2Multiple Myeloma
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
June 2027 (1)
SelinexorPhase 2Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Est. primary completion 2027-06 · NCT05980806 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
SelinexorPhase 2Multiple Myeloma, Refractory
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 June 2027FDA action dateSelinexorPDUFA date for the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗

Recent

17 November 2026Filing acceptedSelinexorFDA accepts the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗
31 August 2026Filing submittedSelinexor (Xpovio)Karyopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
US, FDA · Karyopharm Therapeutics Inc. · Source ↗
30 July 2026Topline resultSelinexor (Xpovio)Phase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Global · Karyopharm Therapeutics Inc. · Source ↗
2 June 2026Topline resultSelinexorSENTRY Phase 3 topline results were mixed
24 March 2026Topline resultSelinexor (Xpovio)Phase 3 SENTRY (NCT04562389) met its first co-primary endpoint (SVR35) and missed its second (Abs-TSS)
Global · Karyopharm Therapeutics Inc. · Source ↗
March 2026WithdrawalSelinexorAccelerated approval in DLBCL voluntarily withdrawn at the FDA's request
US, FDA · Source ↗
16 December 2025ApprovalSelinexorMalaysia approves XPOVIO (selinexor) sNDA for relapsed/refractory DLBCL
MY, NPRA · Source ↗
5 March 2025ApprovalSelinexorXPOVIO approved in Indonesia
ID, BPOM · Source ↗
9 December 2024Topline resultSelinexorBENCH Phase III primary analysis presented: primary endpoint met

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$33M$29M$55M+ $10M short-term inv.$67M-$25M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$35M$34M$91M+ $0 short-term inv.$22M-$23M operating cash flowreport ↗
2025-Q3$44M$31M$38M+ $8.2M short-term inv.$33M-$5.9M operating cash flowreport ↗
2025-Q2$38M$33M$39M+ $13M short-term inv.$37M-$19M operating cash flowreport ↗
2025-Q1$30M$35M$39M+ $31M short-term inv.$23M-$39M operating cash flowreport ↗
2024-Q3$39M$36M$73M+ $61M short-term inv.$32M-$19M operating cash flowreport ↗
2024-Q2$43M$38M$85M+ $67M short-term inv.—-$39M operating cash flowreport ↗
2024-Q1$33M$35M$31M+ $118M short-term inv.$37M-$44M operating cash flowreport ↗
2023-Q3$36M$36M$45M+ $165M short-term inv.$35M-$30M operating cash flowreport ↗
2023-Q2$38M$31M$82M+ $156M short-term inv.$33M-$26M operating cash flowreport ↗
2023-Q1$39M$32M$86M+ $176M short-term inv.$34M-$19M operating cash flowreport ↗
2022-Q3$36M$31M$73M+ $77M short-term inv.$36M-$28M operating cash flowreport ↗
2022-Q2$40M$44M$84M+ $89M short-term inv.$49M-$35M operating cash flowreport ↗
2022-Q1$48M$42M$155M+ $52M short-term inv.$41M-$59M operating cash flowreport ↗
2021-Q3$38M$46M$140M+ $67M short-term inv.$52M-$24M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$146M$126M$61M+ $3.2M short-term inv.$49M-$75M operating cash flowreport ↗

For full-year 2025, Karyopharm reported total revenue of $146.1M, up 0.6% YoY, including U.S. XPOVIO net product revenue of $114.9M. R&D spend was $125.6M, down 12.3% YoY. Cash, cash equivalents, restricted cash and investments totaled $64.1M at December 31, 2025, compared to $109.1M at year-end 2024, and the company reported a full-year net loss of $196.0M.

Management guided full-year 2026 total revenue to $130M-$150M, including U.S. XPOVIO net product revenue of $115M-$130M, with R&D and SG&A expenses of $230M-$245M; existing liquidity is expected to fund current operating plans into the second quarter of 2026. Key clinical catalysts include top-line data from the Phase 3 SENTRY trial in myelofibrosis expected in March 2026, Phase 3 XPORT-EC-042 in endometrial cancer expected in mid-2026, and Phase 3 XPORT-MM-031 in multiple myeloma expected in the second half of 2026. The company also noted expanded global access for selinexor, with approvals in more than 50 countries.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$145M$143M$63M+ $46M short-term inv.$19M-$127M operating cash flowreport ↗
2023-FY$146M$139M$53M+ $139M short-term inv.$36M-$93M operating cash flowreport ↗
2022-FY$157M$149M$137M+ $143M short-term inv.$41M-$150M operating cash flowreport ↗
2021-FY$210M$161M$197M+ $38M short-term inv.$31M-$107M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 21 sales ($351K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-16Abate Kristin · Chief Accounting OfficerOpen-market sale4,788$0.34$2KForm 4
2026-10-01Abate Kristin · Chief Accounting OfficerOpen-market sale378$1.19$450Form 4
2026-09-01Abate Kristin · Chief Accounting OfficerOpen-market sale19$2.02$38Form 4
2026-07-28Poulton Stuart · EVP, Chief Development OfficerOpen-market sale189$7.10$1KForm 4
2026-05-21Greene Barry E · directorAward / grant15,508——Form 4
2026-05-21BOHLIN GAREN G · directorAward / grant15,508——Form 4
2026-05-21Su Zhen · directorAward / grant15,508——Form 4
2026-05-21Schor Chen · directorAward / grant15,508——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 76 reporting institutions held 18.0M shares ($91.2M, 79.6% of shares outstanding).

#InstitutionSharesValue
1Commodore Capital LP1,950,000$10.9M
2RA CAPITAL MANAGEMENT, L.P.1,917,354$10.7M
3ADAGE CAPITAL PARTNERS GP, L.L.C.1,806,322$10.1M
4Avidity Partners Management LP927,482$6.4M
5GOLDMAN SACHS GROUP INC947,579$5.3M
6Catalio Capital Management, LP897,709$5.0M
7VANGUARD CAPITAL MANAGEMENT LLC739,745$4.1M
8Ikarian Capital, LLC733,435$4.1M
9Affinity Asset Advisors, LLC500,000$2.8M
10Soleus Capital Management, L.P.440,000$2.5M
11MILLENNIUM MANAGEMENT LLC420,571$2.3M
12Boxer Capital Management, LLC302,536$1.7M
13Davidson Kempner Capital Management LP300,000$1.7M
14ACORN CAPITAL ADVISORS, LLC287,826$1.6M
15Eversept Partners, LP276,174$1.5M